Holen Sie sich die Stockscreener-App
0.6998
1.82%
-0.013
Handel nachbörslich:
.69
-0.0098
-1.40%
Schlusskurs vom Vortag:
$0.7128
Offen:
$0.7129
24-Stunden-Volumen:
60,059
Relative Volume:
0.02
Marktkapitalisierung:
$3.48M
Einnahmen:
$14.64M
Nettoeinkommen (Verlust:
$-13.74M
KGV:
-0.0668
EPS:
-10.47
Netto-Cashflow:
$-5.04M
1W Leistung:
-0.75%
1M Leistung:
+11.11%
6M Leistung:
-83.14%
1J Leistung:
-93.98%
1-Tages-Spanne:
$0.6907
$0.7233
1-Wochen-Bereich:
$0.69
$0.82
52-Wochen-Spanne:
$0.3611
$11.69
Novabay Pharmaceuticals Inc Stock (NBY) Company Profile
Firmenname
Novabay Pharmaceuticals Inc
Sektor
Branche
Telefon
510-899-8800
Adresse
2000 Powell Street, Suite 1150, Emeryville, CA
Vergleichen Sie NBY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NBY | 0.6998 | 3.48M | 14.64M | -13.74M | -5.04M | -10.47 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-09-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Bestätigt | Laidlaw | Buy |
| 2017-06-05 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-27 | Eingeleitet | Laidlaw | Buy |
| 2017-02-06 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-03-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-14 | Bestätigt | Maxim Group | Buy |
| 2015-04-30 | Fortgesetzt | Maxim Group | Buy |
| 2013-03-06 | Eingeleitet | Ascendiant Capital Markets | Strong Buy |
| 2008-01-03 | Eingeleitet | Dawson James | Speculative Buy |
Alle ansehen
Novabay Pharmaceuticals Inc Aktie (NBY) Neueste Nachrichten
NovaBay calls for affirmative vote on asset sale and dissolution By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Reports Q3 2024 Financials Amid Strategic Changes - TipRanks
NovaBay Pharmaceuticals Reports Third Quarter 2024 Results, Accepts Revised Offer to Sell Avenova Brand - Vision Monday
NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com - Defense World
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
NovaBay accepts higher PRN offer, says Refresh deal no longer superior - MSN
NovaBay agrees to increased offer for eyecare unit - Investing.com
NovaBay agrees to increased offer for eyecare unit By Investing.com - Investing.com UK
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price - StockTitan
NovaBay Pharmaceuticals : Signs Distribution Agreement With the Biopharm Group - Marketscreener.com
# NovaBay Pharmaceuticals Considers Acquisition Offer in Recent SEC Filing - Defense World
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions - MSN
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC - StockTitan
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell Its Avenova Assets - Vision Monday
Novabay Pharmaceuticals Inc (NBY) Stock: A Year of Market Fluctuations - The InvestChronicle
Before You Invest, Make Sure You Check This Novabay Pharmaceuticals Inc (AMEX: NBY) Analysis - Stocks Register
Novabay Pharmaceuticals Inc (NBY)’s Market Momentum: Closing Strong at 0.70, Down -5.62 - The Dwinnex
NovaBay Pharmaceuticals, Inc. announced that it expects to receive $2.83 million in funding from Pioneer Pharma Pte. Ltd. and other investors. - Marketscreener.com
A new trading data show Novabay Pharmaceuticals Inc (NBY) is showing positive returns. - SETE News
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - PR Newswire
NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com - Defense World
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
NBY’s price-to-free cash flow ratio: What it means for investors - US Post News
NovaBay sells Avenova brand to PRN for $9.5 million - Investing.com
PRN Nutriceuticals agreed to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc.. - Marketscreener.com
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders - Business Wire
NovaBay sells Avenova brand to PRN for $9.5 million By Investing.com - Investing.com South Africa
NovaBay Pharma Announces Avenova Sale and Planned Dissolution - TipRanks
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - PR Newswire
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets - StockTitan
NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World
Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.
Was there any good news for Novabay Pharmaceuticals Inc (NBY) stock in the last session? - US Post News
Novabay Pharmaceuticals Inc Inc. (NBY) Price Performance: The Role of Supply and Demand - The InvestChronicle
NovaBay Pharmaceuticals (NYSE:NBY) Announces Quarterly Earnings Results - Defense World
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q2 2024 Earnings Call Transcript - Insider Monkey
Novabay Pharmaceuticals Inc (NBY)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
NovaBay Pharmaceuticals Reports Mixed Second Quarter 2024 Financial Results - Vision Monday
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare By Investing.com - Investing.com Canada
Earnings call: NovaBay Pharmaceuticals reports growth in eyecare - Investing.com
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Crosses Above 50-Day Moving Average of $0.00 - Defense World
NovaBay To Hold 2017 Second Quarter Conference Call On August 10, 2017 - BioSpace
NBY Stock Earnings: NovaBay Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results - wallstreet:online
Ratio Analysis: Unpacking Novabay Pharmaceuticals Inc (NBY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
NBY’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
NovaBay stock hits 52-week low at $0.47 amid steep annual decline - Investing.com
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering - Vision Monday
NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024 - StockTitan
Adversity is less terrifying than hope: Novabay Pharmaceuticals Inc (NBY) - SETE News
NovaBay reports surge in Avenova sales during Prime Day - Investing.com
Finanzdaten der Novabay Pharmaceuticals Inc-Aktie (NBY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):